Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. The company has about ₹500 crores of cash on the balance sheet and generates around ₹100 crores of cash annually. Capital allocation strategy includes dividends and keeping cash reserves for potential opportunities and business expansion. The company is also investing around ₹30-40 crores over the next two years in developing new R&D centers. No specific plans or announcements related to raising debt or equity funding were discussed in the call.

Any current/future capex/capital investment/strategic investment?

Advanced Enzyme Technologies is investing in a new R&D center in Nasik (Pathardi area) on a 15-acre land acquired during COVID times. The R&D building being constructed is around 120,000 square feet, approximately three times their current R&D capacity. Planned R&D capital expenditure for the next two years is ₹30-40 crores. The company is keeping cash reserves (~₹500 crores) available for potential strategic investments or business expansion opportunities. Capital allocation includes continuous investments in R&D setup along with normal capital expenditures. Mukund Kabra indicated expansion p

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects double-digit top-line growth, targeting around 13% to 16% CAGR going forward (Pages 7, 9, 18). EBITDA margin is expected to improve gradually, with a steady-state margin around 33% annually, up from 29% in FY'23 and 33% in FY'24 (Pages 9, 18). Margin expansion is anticipated as growth picks up, especially with improvements expected from the US business and product mix (Pages 7, 8, 18). Earnings growth driven by increased revenues, better product mix, strong cost control, and higher other income as noted in recent quarters (Pages 4, 5, 9). New R&D investments (~₹30-40 crores

Current/ Expected Orderbook/ Pending Orders?

The company does not maintain a formal order book or pending orders. Business operates on an order-to-order basis based on customer needs and market demand. It is difficult to predict exact revenue numbers or future order flow quarter-to-quarter. Customers and orders are somewhat known but there is no structured long-term contract backlog. This approach reflects the nature of the enzyme and bioproducts industry, which is demand-driven and flexible.

Advanced Enzyme Technologies LtdQ4 FY24Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹262P/E: 18.6Market Cap: ₹2.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Future growth expectations for Advanced Enzyme Technologies Limited: - **Overall top-line growth:** Expected between 13% to 16% for FY'25 (Page 8, 18). - **Human nutrition segment:** Anticipated to grow with continued contributions from the US and domestic markets; expected to stabilize between 65%-70% of total business mix over the next 2-3 years (Pages 7, 18). - **US market:** Growth driven by new products in weight and sugar management with 9% growth in FY'24 and positive outlook for FY'25 (Pages 8, 18). - **Bioprocessing segment:** Grew 21% in FY'24; expected decent growth due to new product launches (Page 4, 14). - **Animal nutrition:** Volatile with challenges; 5% decline in FY'24, but expected to stabilize with industry dynamics (Pages 4, 16, 18). - **Product pipeline and R&D:** Significant investment in new R&D facilities (~₹30-40 crores over two years) to drive future innovation and growth (Page 16). - **Probiotics business:** Growth potential linked to combined enzyme-probiotics formulations, though specific targets are unclear (Page 18).

Margin guidance

Category 3

The company expects double-digit top-line growth, targeting around 13% to 16% CAGR going forward (Pages 7, 9, 18).
EBITDA margin is expected to improve gradually, with a steady-state margin around 33% annually, up from 29% in FY'23 and 33% in FY'24 (Pages 9, 18).
Margin expansion is anticipated as growth picks up, especially with improvements expected from the US business and product mix (Pages 7, 8, 18).
Earnings growth driven by increased revenues, better product mix, strong cost control, and higher other income as noted in recent quarters (Pages 4, 5, 9).
New R&D investments (~₹30-40 crores over two years) and product pipeline expansion expected to support sustainable growth (Page 16).
Probiotics and other high-potential areas expected to contribute, though precise margin impact is unclear (Page 18).
The animal nutrition segment may see normal pharma-industry-like growth but remains challenging due to competitive pressures (Page 16).

See what Advanced Enzyme Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity.
The company has about ₹500 crores of cash on the balance sheet and generates around ₹100 crores of cash annually.
Capital allocation strategy includes dividends and keeping cash reserves for potential opportunities and business expansion.
The company is also investing around ₹30-40 crores over the next two years in developing new R&D centers.
No specific plans or announcements related to raising debt or equity funding were discussed in the call.

Order book

The company does not maintain a formal order book or pending orders.
Business operates on an order-to-order basis based on customer needs and market demand.
It is difficult to predict exact revenue numbers or future order flow quarter-to-quarter.
Customers and orders are somewhat known but there is no structured long-term contract backlog.
This approach reflects the nature of the enzyme and bioproducts industry, which is demand-driven and flexible.

See what Advanced Enzyme Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Advanced Enzyme Technologies is investing in a new R&D center in Nasik (Pathardi area) on a 15-acre land acquired during COVID times.
The R&D building being constructed is around 120,000 square feet, approximately three times their current R&D capacity.
Planned R&D capital expenditure for the next two years is ₹30-40 crores.
The company is keeping cash reserves (~₹500 crores) available for potential strategic investments or business expansion opportunities.
Capital allocation includes continuous investments in R&D setup along with normal capital expenditures.
Mukund Kabra indicated expansion plans will be triggered when capacity utilization reaches around 80%, with a current utilization of about 65%.
Expansion will be done gradually in small increments to scale quickly as demand grows.

Track Advanced Enzyme Technologies Ltd — get its next earnings analysis in your feed

How does Advanced Enzyme Technologies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAdvanced Enzyme Technologies Ltd

Rev 3Mar 3

See where Advanced Enzyme Technologies Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Advanced Enzyme Technologies Ltd rank in Pharmaceuticals & Biotechnology?

Compare Advanced Enzyme Technologies Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Advanced Enzyme Technologies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Advanced Enzyme Technologies Ltd Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Advanced Enzyme Technologies Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Advanced Enzyme Technologies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season